<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28900454</article-id><article-id pub-id-type="pmc">5583617</article-id><article-id pub-id-type="publisher-id">JRMS-22-98</article-id><article-id pub-id-type="doi">10.4103/jrms.JRMS_1_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of alpha-lipoic acid supplementation on anthropometric indices and food intake in patients who experienced stroke: A randomized, double-blind, placebo-controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Vida</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Khorvash</surname><given-names>Fariborz</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Feizi</surname><given-names>Awat</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Askari</surname><given-names>Gholamreza</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Department of Epidemiology and Biostatistics, School of Public Health, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Gholamreza Askari, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="askari@mui.ac.ir">askari@mui.ac.ir</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>16</day><month>8</month><year>2017</year></pub-date><volume>22</volume><elocation-id>98</elocation-id><history><date date-type="received"><day>14</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>26</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Journal of Research in Medical Sciences</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Stroke as a devastating condition is a major cause of death worldwide. It is accountable for long-term disability with high personal and social cost in adults. Alpha-lipoic acid (ALA) is an eight-carbon, sulfur-containing compound with antioxidant properties which reduces body weight, changes other anthropometric indices, and regulates food intake by suppressing appetite and increasing metabolism This study was designed to evaluate the possible effects of ALA supplementation on anthropometric indices and dietary intake in patients with stroke.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>In this randomized, double-blind, placebo-controlled clinical trial, 67 patients with stroke were randomly allocated to two groups (taking a 600 mg ALA supplement or placebo daily for 12 weeks). Weight, waist circumference, energy, carbohydrate, protein, and fat intake were measured, and body mass index (BMI) was calculated before and after intervention. Dietary intake and statistical analyses were carried out using Nutritionist IV and SPSS (version 16; SPSS Inc., Chicago, IL, USA) software, respectively.</p></sec><sec id="st3"><title>Results:</title><p>Primary features were similar in the intervention and placebo groups (<italic>P</italic> &#x0003e; 0.05). Waist circumference (<italic>P</italic> &#x0003c; 0.001), energy, carbohydrate, protein, and fat intake (<italic>P</italic> &#x0003c; 0.001) decreased significantly, after the intervention period, in ALA group compared with placebo. While no significant change was observed in weight (<italic>P</italic> = 0.26) and BMI (<italic>P</italic> = 0.56) in ALA supplementation group compared with placebo.</p></sec><sec id="st4"><title>Conclusion:</title><p>Results of this trial indicated that 12-week supplementation with 600 mg ALA can decrease waist circumference and food intake (energy, carbohydrate, protein, and fat) in patients with stroke.</p></sec></abstract><kwd-group><kwd>Alpha-lipoic acid</kwd><kwd>body mass index</kwd><kwd>food intake</kwd><kwd>weight</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Alpha-lipoic acid (ALA) or thioctic acid is an eight-carbon, sulfur-containing compound. Traditionally, it is recognized as a cofactor in the multienzyme complexes that are responsible for the oxidative decarboxylation of &#x003b1;-ketoacids.[<xref rid="ref1" ref-type="bibr">1</xref>] A general agreement exists about the antioxidant properties of ALA, which is thought to function by clearing free radicals directly, chelating metallic ions, enhancing intracellular glutathione, and activating endogenous antioxidant systems.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] Being a strong antioxidant is not the only property of ALA. Studies reported different properties for this cofactor including modulating blood pressure,[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] lipid profile,[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] blood glucose,[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref8" ref-type="bibr">8</xref>] and being a neuroprotective agent.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref9" ref-type="bibr">9</xref>] In addition, there is a large body of growing evidence showing that ALA reduces body weight, changes other anthropometric indices, and regulates food intake by suppressing appetite and increasing metabolism.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]</p><p>Clinical studies have shown that ALA intake up to 1800 mg/day did not show any side effect in humans. It is reported that taking 300&#x02013;600 mg ALA daily is safe for humans.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref>]</p><p>Stroke as a devastating condition is a major cause of death worldwide. It is accountable for long-term disability with high personal and social cost in adults.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] The 2012 BRFSS (Centers for Disease Control and Prevention) data indicated that history of stroke was seen in 2.9% of people &#x02265;18 years of age. In addition, projections show that, by 2030, stroke will be experienced by more people and a 20.5% increase will be observed in prevalence from 2012.[<xref rid="ref18" ref-type="bibr">18</xref>] Metabolic syndrome and obesity are well-known risk factors of coronary artery disease, stroke, and mortality. In addition, metabolic syndrome has been identified as an independent risk factor for acute ischemic noncardioembolic stroke and stroke risk increases along increment in the number of metabolic syndrome components. Two prospective cohort studies confirmed these associations.[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] As we explained that metabolic syndrome components are risk factors of stroke and ALA can modify this component, it can be useful for patients with stroke.</p><p>Although studying the effect of ALA on cardiovascular risk factors such as anthropometric indices and dietary intake is not novel, to the best of our knowledge, the beneficial effects of ALA supplementation in patients who experienced stroke have not been investigated by far. Thus, we designed this study to assay the possible effect of ALA supplementation on anthropometric indices and dietary intake in patients with stroke.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><p>Research Ethics Committee of Isfahan University of Medical Sciences (IUMS) approved the protocol of this randomized, double-blind, placebo-controlled, parallel-designed clinical trial (code: IR.MUI.REC.1395.3.068). In addition, we registered this trial protocol in the Iranian Registry of Clinical Trial (IRCT2016051811763N23).</p><sec id="sec2-1"><title>Study design and participants</title><p>Eighty patients with stroke who referred to Al Zahra Hospital and met the study criteria were enrolled in this trial. The inclusion criteria included filling out informed consent, thrombotic and embolic stroke, body mass index (BMI) = 18.5&#x02013;35, age 30&#x02013;70 years, no specific diseases, and malignancies such as liver disease, kidney disease, and cancer based on self-reports, no vitamin, antioxidant, and omega-3 supplementation. Exclusion criteria included no collaboration, failure to follow the program of trial (compliance &#x0003c;80%), death, experienced gastrointestinal side effects, dizziness, amnesia and eating problems, and recurrent stroke.</p><p>We calculate sample size with power 80% and &#x003b1; = 5% with the following formula. Thirty-three participants were required for each group, which after considering 20% sample loss, forty patients in each group were enrolled.</p><p><inline-graphic xlink:href="JRMS-22-98-g001.jpg"/></p></sec><sec id="sec2-2"><title>Intervention</title><p>We allocated participants randomly into two quantitatively equal groups (in a double-blind parallel manner from randomized number in an eighty-person list): ALA and placebo groups that were taking a 600 mg ALA supplement and similar placebo capsule (containing wheat flour) every day for 12 weeks, respectively. We prepared ALA supplement from Caren company and capsulated it in the School of Pharmacy, IUMS. Thirteen participants were excluded from the study because of different reasons; finally, with 33 and 34 patients remaining in ALA and placebo groups, respectively [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flowchart of participants throughout the intervention</p></caption><graphic xlink:href="JRMS-22-98-g002"/></fig></sec><sec id="sec2-3"><title>Measurements</title><p>At the beginning of the study, we obtained written consent from all volunteers. All data collection and measurements were performed by trained personnel. Body weight was measured by a digital balance to the nearest 0.1 kg with minimal clothing. To measure height, a seca stadiometer was used, and in case of not being able to stand up for measuring height, we determined knee height and the following formula was used:</p><p>Height in centimeters (for men) = 64.19 &#x02013; (0.04 &#x000d7; age) + (2.02 &#x000d7; knee height in centimeters)</p><p>We calculated BMI for each patient (BMI = weight in kg/ht<sup>2</sup> in meters). We measured waist circumference at the level of the iliac crest by an ergonomic circumference measuring tape (model 201; Seca GmbH and Co, KG, Hamburg, Germany). Food intakes were collected by 24-h food recall during face-to-face interviews by a nutritionist (three 24-h food recalls including two midweek days and one weekend day). To assess energy and macronutrient intakes, dietary data were analyzed by Nutritionist IV software (Version 4.1, First Databank Division, The Hearst Corporation, San Bruno, CA, USA). We measured blood pressure by a mercury sphygmomanometer after 5 min of sitting rest.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>All statistical analyses were performed by SPSS (version 16; SPSS Inc., Chicago, IL, USA). Quantitative data are presented as mean &#x000b1; standard deviation. The normality of data was evaluated by Kolmogorov&#x02013;Smirnov test. In case of normal distribution of data, paired <italic>t</italic>-test was used to compare variables before and after the intervention within groups. Comparing the variables after intervention, adjusting for baseline values and in some cases energy intake were performed by analysis of covariance (ANCOVA). All tests were two sided and <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Baseline characteristics were similar in the ALA and placebo groups [<xref ref-type="table" rid="T1">Table 1</xref>]. We found no statistically significant differences in age, weight, height, BMI, waist circumference, blood pressure, energy and macronutrient intake, and fasting blood sugar between two groups before the intervention (<italic>P</italic> &#x0003e; 0.05).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the study participants who received &#x003b1;-lipoic acid (600 mg) or placebo before the intervention</p></caption><graphic xlink:href="JRMS-22-98-g003"/></table-wrap><p>Based on within-group analysis, no significant changes were observed in placebo group for all studied variables (<italic>P</italic> &#x0003e; 0.05), while body weight, BMI, waist circumference, energy, carbohydrate, protein, and fat intake decreased significantly within ALA group (<italic>P</italic> &#x0003c; 0.001).</p><p>Based on ANCOVA results, statistically significant reductions were observed for waist circumference (<italic>P</italic> &#x0003c; 0.001), energy, carbohydrate, protein, and fat intake (<italic>P</italic> &#x0003c; 0.001), and there were no differences for weight (<italic>P</italic> = 0.26) and BMI (<italic>P</italic> = 0.56) in ALA supplementation group compared with placebo group [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Anthropometric indices and food intake of the the study participants before and after supplementation in both groups</p></caption><graphic xlink:href="JRMS-22-98-g004"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>This study results indicate that 12-week consumption of 600 mg ALA has no effect on body weight and BMI, but can reduce waist circumference, energy, carbohydrate, protein, and fat intake in patients with stroke. According to our knowledge, the present trial is the first study, which investigated the effect of ALA consumption on anthropometric indices and food intake in patients with stroke.</p><p>Our results indicate that ALA could change weight and BMI within group, but this change was not significant between groups after eliminating the confounding effect of energy intake. It means that these changes were because of reduction in food intake. However, changes in waist circumference (confounding effect of energy intake eliminated), energy, carbohydrate, protein, and fat intake were significant.</p><p>There is a large body of growing evidence indicating that ALA supplementation can play an important role in the regulation of food intake and anthropometric indices by suppressing appetite and elevating energy metabolism.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref23" ref-type="bibr">23</xref>] In agreement with our study, there are four human studies; Mohammadi <italic>et al</italic>.[<xref rid="ref5" ref-type="bibr">5</xref>] evaluated the effects of ALA supplementation in men with spinal cord injury. In a randomized, double-blind, placebo-controlled, 12-week trial, they demonstrated that 600 mg ALA could reduce body weight, BMI, waist circumference, energy, and macronutrients significantly. Based on our search, this is the only study which measured energy intake, but they did not control the effect of changes in energy intake in their result analysis. It seems that if they would have taken the energy intake component into account, different results would have been reported.</p><p>In another randomized, double-blind, placebo-controlled, 20-week trial by Koh <italic>et al</italic>.,[<xref rid="ref12" ref-type="bibr">12</xref>] 1800 mg LA reduced body weight significantly more than did 1200 mg LA and placebo in 360 obese individuals. In addition, 20-week supplementation with 600 mg ALA decreased BMI in obese patients with diabetes mellitus and signs of peripheral polyneuropathia.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Kim <italic>et al</italic>.[<xref rid="ref11" ref-type="bibr">11</xref>] in a case series studied the effect of ALA on antipsychotics-induced weight gain in schizophrenic patients (<italic>n</italic> = 7, 1200 mg LA, 12 weeks). A remarkable reduction in weight (3.2 kg mean weight loss) and BMI was observed. Except the study of Mohammadi <italic>et al</italic>., none of the aforementioned studies considered energy and macronutrient intake and neither of them took the confounding effect of energy intake into account.</p><p>Several animal[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref10" ref-type="bibr">10</xref>] and human studies[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref12" ref-type="bibr">12</xref>] have shown that ALA supplementation reduces appetite, weight, fat tissue, and restricts weight gain. Studies have shown that the effect of LA is not because of its toxicity.[<xref rid="ref10" ref-type="bibr">10</xref>] Uncoupling protein-1 (UCP-1), located in the inner mitochondrial membrane, is the main regulator of energy metabolism in rodents. ALA supplementation increases UCP-1-messenger RNA expression.[<xref rid="ref10" ref-type="bibr">10</xref>] On the other hand, ALA supplementation reduces appetite by suppressing hypothalamic adenosine5&#x02019;-monophosphate-activated protein kinase.[<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref>] It has been well known that the hypothalamus is the appetite center in the brain.[<xref rid="ref10" ref-type="bibr">10</xref>]</p><p>Being a strong antioxidant is not the only property of ALA. Studies reported different properties for this cofactor including modulating blood pressure,[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] lipid profile,[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] blood glucose,[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref8" ref-type="bibr">8</xref>] and being a neuroprotective agent.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref9" ref-type="bibr">9</xref>] Metabolic syndrome and obesity are well-known risk factors of coronary artery disease and stroke.[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>] Therefore, it seems ALA can modify risk factors of stroke.</p><p>There are several limitations for this trial, which is better to be counted in the interpretation of our results, including sample size and restricted duration of the study. In addition, we were not able to measure body composition and metabolism.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Based on this randomized, double-blind, placebo-controlled, parallel-designed clinical trial results, supplementation with 600 mg ALA for 12 weeks can decrease some anthropometric parameters (waist circumference) and food intake in patients with stroke. Therefore, ALA could be a risk modifier for patients with stroke.</p><sec id="sec2-5"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-6" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>L</given-names></name><name><surname>Witt</surname><given-names>EH</given-names></name><name><surname>Tritschler</surname><given-names>HJ</given-names></name></person-group><article-title>Alpha-lipoic acid as a biological antioxidant</article-title><source>Free Radic Biol Med</source><year>1995</year><volume>19</volume><fpage>227</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">7649494</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>Alpha-lipoic acid: A metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury</article-title><source>Drug Metab Rev</source><year>1998</year><volume>30</volume><fpage>245</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">9606603</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>L</given-names></name><name><surname>Tritschler</surname><given-names>HJ</given-names></name><name><surname>Wessel</surname><given-names>K</given-names></name></person-group><article-title>Neuroprotection by the metabolic antioxidant alpha-lipoic acid</article-title><source>Free Radic Biol Med</source><year>1997</year><volume>22</volume><fpage>359</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">8958163</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasdev</surname><given-names>S</given-names></name><name><surname>Gill</surname><given-names>VD</given-names></name><name><surname>Parai</surname><given-names>S</given-names></name><name><surname>Gadag</surname><given-names>V</given-names></name></person-group><article-title>Effect of moderately high dietary salt and lipoic acid on blood pressure in Wistar-Kyoto rats</article-title><source>Exp Clin Cardiol</source><year>2007</year><volume>12</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">18650986</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>V</given-names></name><name><surname>Khalili</surname><given-names>M</given-names></name><name><surname>Eghtesadi</surname><given-names>S</given-names></name><name><surname>Dehghani</surname><given-names>S</given-names></name><name><surname>Jazayeri</surname><given-names>S</given-names></name><name><surname>Aghababaee</surname><given-names>SK</given-names></name><etal/></person-group><article-title>The effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in men with chronic spinal cord injury: A clinical trial</article-title><source>Spinal Cord</source><year>2015</year><volume>53</volume><fpage>621</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25753493</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>EY</given-names></name><name><surname>Ha</surname><given-names>AW</given-names></name><name><surname>Kim</surname><given-names>WK</given-names></name></person-group><article-title>&#x003b1; - Lipoic acid reduced weight gain and improved the lipid profile in rats fed with high fat diet</article-title><source>Nutr Res Pract</source><year>2012</year><volume>6</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">22808342</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thirunavukkarasu</surname><given-names>V</given-names></name><name><surname>Anitha Nandhini</surname><given-names>AT</given-names></name><name><surname>Anuradha</surname><given-names>CV</given-names></name></person-group><article-title>Effect of alpha-lipoic acid on lipid profile in rats fed a high-fructose diet</article-title><source>Exp Diabesity Res</source><year>2004</year><volume>5</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15512787</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Alpha-lipoic acid supplementation and diabetes</article-title><source>Nutr Rev</source><year>2008</year><volume>66</volume><fpage>646</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19019027</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilska</surname><given-names>A</given-names></name><name><surname>Wlodek</surname><given-names>L</given-names></name></person-group><article-title>Lipoic acid &#x02013; The drug of the future?</article-title><source>Pharmacol Rep</source><year>2005</year><volume>57</volume><fpage>570</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16227639</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Namkoong</surname><given-names>C</given-names></name><name><surname>Jang</surname><given-names>PG</given-names></name><name><surname>Ryu</surname><given-names>JW</given-names></name><name><surname>Song</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>727</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15195087</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Cho</surname><given-names>HS</given-names></name></person-group><article-title>A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia</article-title><source>J Clin Psychopharmacol</source><year>2008</year><volume>28</volume><fpage>138</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">18344723</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>EH</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Lee</surname><given-names>SA</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Cho</surname><given-names>EH</given-names></name><name><surname>Jeong</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of alpha-lipoic Acid on body weight in obese subjects</article-title><source>Am J Med</source><year>2011</year><volume>124</volume><fpage>85.e1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21187189</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto-Hontoria</surname><given-names>PL</given-names></name><name><surname>P&#x000e9;rez-Matute</surname><given-names>P</given-names></name><name><surname>Fern&#x000e1;ndez-Galilea</surname><given-names>M</given-names></name><name><surname>Barber</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>JA</given-names></name><name><surname>Moreno-Aliaga</surname><given-names>MJ</given-names></name></person-group><article-title>Lipoic acid prevents body weight gain induced by a high fat diet in rats: Effects on intestinal sugar transport</article-title><source>J Physiol Biochem</source><year>2009</year><volume>65</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19588730</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goraca</surname><given-names>A</given-names></name><name><surname>Huk-Kolega</surname><given-names>H</given-names></name><name><surname>Piechota</surname><given-names>A</given-names></name><name><surname>Kleniewska</surname><given-names>P</given-names></name><name><surname>Ciejka</surname><given-names>E</given-names></name><name><surname>Skibska</surname><given-names>B</given-names></name></person-group><article-title>Lipoic acid &#x02013; Biological activity and therapeutic potential</article-title><source>Pharmacol Rep</source><year>2011</year><volume>63</volume><fpage>849</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">22001972</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Therapy of endocrine disease: A systematic review and meta-analysis of &#x003b1;-lipoic acid in the treatment of diabetic peripheral neuropathy</article-title><source>Eur J Endocrinol</source><year>2012</year><volume>167</volume><fpage>465</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">22837391</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berressem</surname><given-names>D</given-names></name><name><surname>Koch</surname><given-names>K</given-names></name><name><surname>Franke</surname><given-names>N</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Eckert</surname><given-names>GP</given-names></name></person-group><article-title>Intravenous treatment with a long-chain Omega-3 lipid emulsion provides neuroprotection in a murine model of ischemic stroke &#x02013; A pilot study</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0167329</fpage><pub-id pub-id-type="pmid">27902774</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jauch</surname><given-names>EC</given-names></name><name><surname>Saver</surname><given-names>JL</given-names></name><name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name><surname>Bruno</surname><given-names>A</given-names></name><name><surname>Connors</surname><given-names>JJ</given-names></name><name><surname>Demaerschalk</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>870</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">23370205</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Berry</surname><given-names>JD</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>AHA statistical update</article-title><source>Circulation</source><year>2013</year><volume>127</volume><fpage>e62</fpage><lpage>245</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HJ</given-names></name><name><surname>Bai</surname><given-names>CH</given-names></name><name><surname>Yeh</surname><given-names>WT</given-names></name><name><surname>Chiu</surname><given-names>HC</given-names></name><name><surname>Pan</surname><given-names>WH</given-names></name></person-group><article-title>Influence of metabolic syndrome and general obesity on the risk of ischemic stroke</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>1060</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16514099</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>YF</given-names></name><name><surname>Hu</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>IF</given-names></name><name><surname>Lai</surname><given-names>YJ</given-names></name><name><surname>Su</surname><given-names>VY</given-names></name><name><surname>Pan</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Associations of metabolic syndrome and its components with mortality in the elderly: A cohort study of 73,547 Taiwanese Adults</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><fpage>e956</fpage><pub-id pub-id-type="pmid">26061328</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahreynian</surname><given-names>M</given-names></name><name><surname>Kelishadi</surname><given-names>R</given-names></name><name><surname>Qorbani</surname><given-names>M</given-names></name><name><surname>Motlagh</surname><given-names>ME</given-names></name><name><surname>Kasaeian</surname><given-names>A</given-names></name><name><surname>Ardalan</surname><given-names>G</given-names></name><etal/></person-group><article-title>Weight disorders and anthropometric indices according to socioeconomic status of living place in Iranian children and adolescents: The CASPIAN-IV study</article-title><source>J Res Med Sci</source><year>2015</year><volume>20</volume><fpage>440</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">26487872</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohtashami</surname><given-names>A</given-names></name><name><surname>Entezari</surname><given-names>MH</given-names></name></person-group><article-title>Effects of <italic>Nigella sativa</italic> supplementation on blood parameters and anthropometric indices in adults: A systematic review on clinical trials</article-title><source>J Res Med Sci</source><year>2016</year><volume>21</volume><fpage>3</fpage><pub-id pub-id-type="pmid">27904549</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okanovic</surname><given-names>A</given-names></name><name><surname>Prnjavorac</surname><given-names>B</given-names></name><name><surname>Jusufovic</surname><given-names>E</given-names></name><name><surname>Sejdinovic</surname><given-names>R</given-names></name></person-group><article-title>Alpha-lipoic acid reduces body weight and regulates triglycerides in obese patients with diabetes mellitus</article-title><source>Med Glas (Zenica)</source><year>2015</year><volume>12</volume><fpage>122</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26276648</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Ikuta</surname><given-names>N</given-names></name><name><surname>Okano</surname><given-names>A</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Nakata</surname><given-names>D</given-names></name><name><surname>Terao</surname><given-names>K</given-names></name><etal/></person-group><article-title>Isomeric effects of anti-diabetic &#x003b1;-lipoic acid with &#x003b3;-cyclodextrin</article-title><source>Life Sci</source><year>2015</year><volume>136</volume><fpage>73</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26141985</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Galilea</surname><given-names>M</given-names></name><name><surname>P&#x000e9;rez-Matute</surname><given-names>P</given-names></name><name><surname>Prieto-Hontoria</surname><given-names>PL</given-names></name><name><surname>S&#x000e1;inz</surname><given-names>N</given-names></name><name><surname>L&#x000f3;pez-Yoldi</surname><given-names>M</given-names></name><name><surname>Houssier</surname><given-names>M</given-names></name><etal/></person-group><article-title>&#x003b1;-lipoic acid reduces fatty acid esterification and lipogenesis in adipocytes from overweight/obese subjects</article-title><source>Obesity (Silver Spring)</source><year>2014</year><volume>22</volume><fpage>2210</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">25045030</pub-id></element-citation></ref></ref-list></back></article>